Cancer Dx startup Microlin Bio envisions $25M IPO

Microlin Bio has filed plans to raise up to $25 million in an initial public offering designed to advance work on tests and related therapies for lung, ovarian, colorectal and prostate cancers. The New York startup was incorporated in July 2013. Microlin plans to trade on the Nasdaq under the symbol "MCLB." Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.